Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | HPGD | P15428 | 5/20 | 0.76 |
| ▸ | SLCO2B1 | O94956 | 4/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.76 |
| ▸ | DAPK1 | P53355 | 4/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.76 |
| ▸ | APEX1 | P27695 | 3/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.76 |
| ▸ | RAD52 | P43351 | 1/20 | 0.76 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.76 |
| ▸ | TST | Q16762 | 1/20 | 0.76 |
| ▸ | BCL9 | O00512 | 6/20 | 0.67 |
| ▸ | CTNNB1 | P35222 | 6/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Herbacetin SCHEMBL31442430 | 1.00 | FBP1 (1.00) | FBP1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL16682485 | 0.88 | FBP1 (0.78) | FBP1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL26204956 | 0.88 | FBP1 (0.78) | FBP1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL6567404 | 0.87 | FBP1 (0.76) | FBP1MEN1MAPTKMT2AKDM4E | |
| Gossypetin SCHEMBL29929428 | 0.86 | MEN1 (1.00) | FBP1MEN1MAPTKMT2AKDM4E | |
| Gossypetin SCHEMBL157033 | 0.86 | MEN1 (1.00) | FBP1MEN1MAPTKMT2AKDM4E | |
| Gossypetin SCHEMBL29419067 | 0.86 | MEN1 (1.00) | FBP1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL12640014 | 0.85 | MEN1 (0.77) | FBP1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL30190288 | 0.85 | MEN1 (0.77) | FBP1MEN1MAPTKMT2AKDM4E | |
| Gossypetin SCHEMBL16782915 | 0.85 | MEN1 (0.97) | FBP1MEN1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| EP-4583889-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | Iovance Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2025067472-A1 | METHODS OF CULTURING GAMMA DELTA T CELLS | NANJING LEGEND BIOTECH CO., LTD. (CN) | 2025-04-03 | — | — | WO | claimed |
| WO-2025015318-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | claimed |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. | 2025-01-02 | — | — | US | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2024-11-07 | — | — | US | claimed |
| EP-4404969-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-06-13 | — | — | US | claimed |
| EP-3418274-A1 | METHOD FOR EXTRACTING HERBACETIN FROM RHODIOLA ROSEA | Taizhou Forever Biotechnology Co., Ltd. (CN) | 2018-12-26 | — | — | EP | claimed |
| US-20180354926-A1 | Method for Extracting Herbacetin from Plants of Rhodiola L. | Taizhou Danding Biotechnology Co., Ltd. (CN) | 2018-12-13 | — | — | US | claimed |
| US-20140303244-A1 | METHODS OF TREATING CANCER WITH HERBACETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-09 | — | — | US | claimed |
| WO-2013075120-A1 | METHODS OF TREATING CANCER WITH HERBACETIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2013-05-23 | — | — | WO | claimed |
| CN-101879156-B | Medicinal composition and application thereof | SHANGHAI INST PHARM INDUSTRY | 2013-01-30 | — | — | CN | claimed |
| CN-101879156-A | Medicinal composition and application thereof | SHANGHAI INST PHARM INDUSTRY | 2010-11-10 | — | — | CN | claimed |
| WO-2009151173-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF VIRAL DISEASES CONTAINING RHODIOLA EXTRACTS, FRACTIONS, THE ISOLATED FLAVONOID COMPOUNDS THEREFROM, DERIVATIVES COMPOUNDS THEREOF OR THE PHARMACEUTICALLY ACCEPTABLE SALTS AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-17 | — | — | WO | claimed |
| CN-101119719-A | The use of flavonol and flavonol glycosides for stimulating growth of renal tubular epithelial cells to secrete the kidney secreting bone growth factor | MIAN LONG (US) | 2008-02-06 | — | — | CN | claimed |
| US-20080009451-A1 | Applications of kidney secreted bone growth factor and pharmaceutical use of flavonol and flavonol glycosides for stimulating the secretion of kidney secreted bone growth factor | LONG MIAN | 2008-01-10 | — | — | US | claimed |
| EP-1847265-A1 | THE USE OF FLAVONOL AND FLAVONOL GLYCOSIDES FOR STIMULATING GROWTH OF RENAL TUBULAR EPITHELIAL CELLS TO SECRETE THE KIDNEY SECRETING BONE GROWTH FACTOR | Long, Mian (US) | 2007-10-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | FBP1 4326/4885MEN1 3114/4885MAPT 2664/4885 |
| US-20140303244-A1 | METHODS OF TREATING CANCER WITH HERBACETIN | ALDOA, DERA, GAPDH | FBP1 214/4885MEN1 1153/4885MAPT 2719/4885 |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | CD69, CD209, ICOS | FBP1 2076/4885MEN1 4832/4885MAPT 4516/4885 |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | NFATC1, MKI67, ICOS | FBP1 3808/4885MEN1 3972/4885MAPT 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.